版本:
中国

BRIEF-Tapimmune says on track to achieve 50 pct enrollment in ongoing phase 2 dosing study of TPIV 200

May 31 Tapimmune Inc

* Tapimmune provides first quarter 2017 corporate and clinical update

* Says for 2Q 2017: on track to achieve 50% enrollment in ongoing phase 2 dosing study of TPIV 200 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐